Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085)

NCT00759109 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Hepatocellular

Interventions

BIOLOGICAL: Peginterferon alfa-2b
OTHER: Observation (no treatment)

Sponsor

Merck Sharp & Dohme LLC